EU’s Avastin Policy: A Stark Contrast To The FDA’s Recent Decision
The Wall Street Journal: EU Backs Avastin For Breast CancerThe committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients. While the FDA plans to revoke approval of Avastin, the U.S. regulator has granted Roche a hearing later this year, though analysts say the Swiss drug maker is unlikely to change the U.S. watchdog's views (Mijuk, 3/2). This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
